05/17/22 7:30 AMNasdaq : ABUS conferencesArbutus to Present at H.C. Wainwright Global Investment ConferenceArbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that William Collier, Arbutus’RHEA-AIneutral
05/05/22 7:30 AMNasdaq : ABUS earningsArbutus Reports First Quarter 2022 Financial Results and Provides Corporate UpdateRHEA-AIneutral
04/21/22 7:30 AMNasdaq : ABUS conferencesearningsArbutus to Report First Quarter 2022 Financial Results and Provide Corporate UpdateArbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled itsRHEA-AIneutral
03/03/22 7:30 AMNasdaq : ABUS earningsArbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate UpdateAnticipate reporting data from four clinical trials in chronically infected HBV patients in 2022 Expected to complete IND-enabling studies for two oral compounds (PD-L1 inhibitor AB-101 and RNA destabilizer AB-161) to treat HBV in the second half of 2022 Anticipate advancing an oral compound thatRHEA-AIneutral
02/28/22 6:02 AMNasdaq : ABUS Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against ModernaArbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Genevant Sciences today filed a lawsuit inRHEA-AInegative
02/17/22 7:30 AMNasdaq : ABUS conferencesearningsArbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate UpdateArbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled itsRHEA-AIneutral
01/24/22 7:30 AMNasdaq : ABUS Arbutus Announces 2022 Corporate Objectives and Provides Financial UpdateMultiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies Complete IND-enabling studies for oral PD-L1 inhibitor, AB-101, for the treatment of HBV Complete IND-enabling studies for next generation oral RNA destabilizer, AB-161,RHEA-AIneutral
01/04/22 7:30 AMNasdaq : ABUS conferencesArbutus to Participate at H.C. Wainwright Bioconnect Virtual ConferenceArbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people withRHEA-AIneutral
12/14/21 7:30 AMNasdaq : ABUS clinical trialAntios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus InfectionAntios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis B virus (HBV)RHEA-AIneutral
12/13/21 7:30 AMNasdaq : ABUS partnershipArbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and TaiwanQilu Pharmaceutical, one of the leading pharmaceutical companies in China, becomes strategic partner to provide development, manufacturing and commercialization expertise for the mainland China, Hong Kong, Macau and Taiwan markets Arbutus to receive $40 million in an upfront payment, up to $245RHEA-AIpositive